Halozyme Therapeutics Inc

NAS:HALOHealthcareNASDAQ:NBINASDAQ:NQUSMG

$122.50+0.54%At closeAt close · Tue 20 Oct · ≈ AED 449.88 · Market cap $13.9B · Next earnings Mon 2 Nov · Extended $122.87 +0.30%

USD billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM	YoY
Revenue	0.3	0.4	0.7	0.8	1.0	1.4	1.7	+19.1%
Cost of revenue	0.0	0.1	0.1	0.2	0.2	0.3	0.3	+5.4%
Gross profit	0.2	0.4	0.5	0.6	0.9	1.1	1.3	+16.5%
Research & development	0.0	0.0	0.1	0.1	0.1	0.1	—	—
Selling, general & administrative	0.0	0.1	0.1	0.1	0.2	0.2	—	—
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Operating expenses	0.1	0.1	0.3	0.3	0.3	0.3	1.0	+248.4%
Operating income	0.1	0.3	0.3	0.3	0.6	0.8	0.6	−26.8%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	+12.0%
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other income / expense	(0.0)	(0.0)	(0.0)	0.0	0.0	(0.3)	—	—
Pre-tax income	0.1	0.2	0.2	0.3	0.6	0.5	0.6	+24.9%
Income tax	0.0	(0.2)	0.0	0.1	0.1	0.1	0.2	+13.2%
Net income	0.1	0.4	0.2	0.3	0.4	0.3	0.4	+30.5%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—	—
EPS, basic (per share)	0.95	2.86	1.48	2.13	3.50	2.64	3.52	+33.2%
EPS, diluted (per share)	0.91	2.74	1.44	2.10	3.43	2.56	3.35	+30.7%
EBITDA	0.2	0.3	0.3	0.5	0.7	0.6	0.6	+12.2%
Depreciation & amortization	0.0	0.0	0.0	0.1	0.1	0.1	0.0	−49.8%
Weighted average shares (shares)	136,206,000	140,646,000	136,844,000	131,927,000	126,827,000	119,840,000	—	—
Weighted average diluted shares (shares)	141,463,000	146,796,000	140,608,000	134,197,000	129,424,000	123,904,000	—	—
Gross margin	83.8%	81.6%	78.9%	76.8%	84.3%	78.1%	76.4%	−1.7 pts
Operating margin	53.9%	62.2%	40.5%	40.7%	54.3%	58.4%	35.9%	−22.6 pts
Net margin	48.2%	90.8%	30.6%	34.0%	43.7%	22.7%	24.9%	+2.2 pts